This paper describes methods for promoting research and development (R&D) on health crisis management, which is destined to manage something that is considered to be unmanageable, by comparing it with R&D on intractable & rare diseases, which continues the challenge of establishing treatment methods for incurable diseases.
Health crisis consists of two components. One is the health crisis event, which indicates the cause of a health crisis, including natural disaster, crime, radiation accident, terrorism, etc., and the other is the health crisis situation, which indicates a state where people’s life and safety is threatened by the health crisis event, including panic, insufficiency in refuge, shortage of food, water, and daily necessities, the malfunction of command system or medical services delivery system, etc. Although the former is not able to be managed, the latter can be managed, and the management technology for it can be developed and established. Therefore, focusing on not the event but the situation, R&D for health crisis management should be promoted through the following steps: (1) to seek the seeds for a management technology that is effective for a situation caused by one event, (2) to evaluate whether the technology is applicable to a similar situation caused by the other event and to establish the management technology for a certain situation, and (3) to establish a management technology system, which is able to respond to all possible situations that can be caused by a certain event.
Health crisis can be defined based on four requirements, that is, (1) the cause of the crisis is not clear; (2) a management method for the crisis has not been established; (3) the occurrence of the crisis is rare; and (4) the crisis imposes a severe and long-term burden on the people, by referring to requirements for intractable & rare diseases. Of these, “rarity” is the most influential factor for inhibiting the progress of science and technology. Nevertheless, in R&D for intractable & rare diseases, various efforts are being made to overcome the rarity, which include the operation of a (patient) registry, the drug and medical device development pipeline, and the development of evidence-based guidelines that are composed of some clinical questions (CQs). Because there is little evidence related to health crisis management, it may be difficult to make recommendations for CQs with a high level of evidence. However, by considering the CQs as research questions, a new R&D to establish evidence for health crisis management can be established.
View full abstract